Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of First-line Anti-TB Drugs in HIV+/- Patients on Thai-Myanmar Border
NCT02457208Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Jul 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of isoniazid, rifampicin, pyrazinamide and ethambutol in pulmonary tuberculosis (TB), sponsored by University of Oxford. Primary endpoints: Plasma drug levels of Rifampicin at 6 Months, Plasma drug levels of Isoniazid at 6 Months and 2 more. Started Jul 2015; status: completed.
02
Drugs
isoniazidrifampicinpyrazinamideethambutol
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT02457208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02457208.